Informations sur le produit
- N-Ethyl-N-methylcarbamic acid (3R)-2,3-dihydro-3-(2-propyn-1-ylamino)-1H-inden-5-yl ester (2R,3R)-2,3-dihydroxybutanedioateTV 3326
- (3R)-3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-yl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (2:1)
- Carbamic acid, N-ethyl-N-methyl-, (3R)-2,3-dihydro-3-(2-propyn-1-ylamino)-1H-inden-5-yl ester, (2R,3R)-2,3-dihydroxybutanedioate (2:1)
- Carbamic acid, ethylmethyl-, (3R)-2,3-dihydro-3-(2-propynylamino)-1H-inden-5-yl ester, (2R,3R)-2,3-dihydroxybutanedioate (2:1)
- Ethylmethyl-carbamic acid (3R)-2,3-dihydro-3-(2-propynylamino)-1H-inden-5-yl ester (2R,3R)-2,3-dihydroxybutanedioate (2:1)
- Tv 3326
Ladostigil tartrate is an aminopyridine drug that has been used to treat neurodegenerative diseases, such as Alzheimer's disease. Ladostigil tartrate is a pro-drug of carbamic acid and butyrylcholinesterase inhibitor. This medication binds to the active site of acetylcholine esterase (AChE) and blocks its activity. This allows more acetylcholine to accumulate in the synapses, which results in increased stimulation of postsynaptic receptors. Ladostigil tartrate also has neuroprotective effects and has been shown to reduce microglial activation and pro-inflammatory cytokines in mice models for Alzheimer's disease.